Profusa to Acquire PanOmics Assay Know-How for $30M in Highly Dilutive Stock, Seeks $10M Additional Equity

summarizeSummary

Profusa entered a definitive agreement to acquire PanOmics Assay know-how for $30 million in convertible preferred stock, contingent on shareholder approval, and committed to raising an additional $10 million in equity, signaling extreme dilution for the financially distressed company.

check_boxKey Events

• Acquisition of PanOmics Assay Know-How

  Profusa entered a definitive Asset Purchase Agreement to acquire substantially all know-how assets related to Bio Insights LLC's PanOmics Assay, an integrated multi-omics analysis platform.

• $30 Million Purchase Price in Convertible Preferred Stock

  The aggregate purchase price of $30,000,000 will be paid through the issuance of a newly created Series A Convertible Preferred Stock, convertible into common stock one year post-issuance, subject to shareholder approval.

• Significant Future Equity Dilution Planned

  The company committed to making best efforts to raise an additional $10,000,000 in equity financing concurrently with or within 30 days following the closing of the acquisition.

• Substantial Management Equity Awards

  The Board will approve the issuance of common stock equal to 12% of the fully diluted shares to the CEO and CFO for retention, also subject to stockholder approval.

auto_awesomeAnalysis

Profusa, a company previously reporting zero revenue and a going concern warning, has entered into a definitive agreement to acquire the PanOmics Assay know-how for $30 million. The purchase price will be satisfied through the issuance of a new series of non-voting convertible preferred stock, which will convert into common stock one year after issuance. This transaction is highly dilutive and requires shareholder approval. In addition to this substantial stock-based acquisition, the company has committed to raising an additional $10 million in equity financing concurrently with or shortly after the closing, further indicating a critical need for capital. The agreement also includes a provision for issuing 12% of the fully diluted common stock to management (CEO and CFO) upon shareholder approval, which represents a significant compensation package amidst the company's financial challenges. The seller will also receive a board seat and has agreed to vote its shares in line with the Board's recommendations. This filing provides the detailed terms of the acquisition previously announced in news, highlighting the extreme dilution and ongoing capital requirements for the company's survival and strategic pivot.